MA56525B1 - Dérivés de benzisoxazole sulfonamide - Google Patents

Dérivés de benzisoxazole sulfonamide

Info

Publication number
MA56525B1
MA56525B1 MA56525A MA56525A MA56525B1 MA 56525 B1 MA56525 B1 MA 56525B1 MA 56525 A MA56525 A MA 56525A MA 56525 A MA56525 A MA 56525A MA 56525 B1 MA56525 B1 MA 56525B1
Authority
MA
Morocco
Prior art keywords
compounds
sulfonamide derivatives
patients
cell growth
abnormal cell
Prior art date
Application number
MA56525A
Other languages
English (en)
Other versions
MA56525A (fr
Inventor
Robert Arnold Kumpf
Pei-Pei Kung
Scott Channing Sutton
Samantha Elizabeth Greasley
Robert Louis Hoffman
Paul Francis Richardson
Ylva Elisabet Bergman Bozikis
Oleg Brodsky
Michelle Ang Camerino
Paul Anthony Stupple
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Priority claimed from PCT/IB2020/055589 external-priority patent/WO2020254946A1/fr
Publication of MA56525A publication Critical patent/MA56525A/fr
Publication of MA56525B1 publication Critical patent/MA56525B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés de formule (i) ou des sels pharmaceutiquement acceptables de ceux-ci, dans laquelle le cycle a, r1-r8 et n ont la signification indiquée dans la description. Les nouveaux dérivés de benzisoxazole sulfonamide sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez des patients. D'autres modes de réalisation concernent des compositions pharmaceutiques contenant les composés et des méthodes d'utilisation des composés et des compositions dans le traitement d'une croissance cellulaire anormale chez des patients.
MA56525A 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide MA56525B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
PCT/IB2020/055589 WO2020254946A1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Publications (2)

Publication Number Publication Date
MA56525A MA56525A (fr) 2022-04-27
MA56525B1 true MA56525B1 (fr) 2024-02-29

Family

ID=80633360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56525A MA56525B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Country Status (2)

Country Link
AR (1) AR119747A1 (fr)
MA (1) MA56525B1 (fr)

Also Published As

Publication number Publication date
AR119747A1 (es) 2022-01-05
MA56525A (fr) 2022-04-27

Similar Documents

Publication Publication Date Title
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA54327B1 (fr) Inhibiteurs de kras g12c
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TN2009000544A1 (fr) Derives de benzimidazole
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
MA28747B1 (fr) Dérivés de pyridine
MA31419B1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA31894B1 (fr) Composes organiques
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA24729A1 (fr) Macrolides nouveaux.
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf